Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes

Rachel Phelan; Min Chen; Caitrin Bupp; Yung Tsi Bolon; Larisa Broglie; Janet Brunner-Grady; Linda J. Burns; Saurabh Chhabra; Debra Christianson; Rachel Cusatis; Steven M. Devine; Anita D'Souza; Mary Eapen; Mehdi Hamadani; Mary Hengen; Stephanie J. Lee; Amy Moskop; Kristin M. Page; Marcelo Pasquini; Waleska S. Pérez; Marcie Riches; Doug Rizzo; Wael Saber; Stephen R. Spellman; Heather E. Stefanski; Patricia Steinert; Daniel Weisdorf; Mary Horowitz; Jeffery J. Auletta; Bronwen E. Shaw; Mukta Arora

doi:10.1016/j.jtct.2022.04.012

Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes

Rachel Phelan, Min Chen, Caitrin Bupp, Yung Tsi Bolon, Larisa Broglie, Janet Brunner-Grady, Linda J. Burns, Saurabh Chhabra, Debra Christianson, Rachel Cusatis, Steven M. Devine, Anita D'Souza, Mary Eapen, Mehdi Hamadani, Mary Hengen, Stephanie J. Lee, Amy Moskop, Kristin M. Page, Marcelo Pasquini, Waleska S. PérezMarcie Riches, Doug Rizzo, Wael Saber, Stephen R. Spellman, Heather E. Stefanski, Patricia Steinert, Daniel Weisdorf, Mary Horowitz, Jeffery J. Auletta, Bronwen E. Shaw, Mukta Arora

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Hematopoietic cell transplantation (HCT) has been successfully used to treat many malignant and nonmalignant conditions. As supportive care, donor selection, and treatment modalities evolve, documenting HCT trends and outcomes is critical. This report from the Center for International Blood and Marrow Transplant Research (CIBMTR) provides an update on current transplantation activity and survival rates in the United States. Additional data on the use and outcomes of HCT in the adolescent and young adult (AYA) population are included. AYA patients more frequently receive peripheral blood stem cell grafts than pediatric patients, which may reflect differences in practice in pediatric versus adult treatment centers. The proportions of donor types also differ those in adult and pediatric populations. Outcomes for patients in the AYA age range are similar to those of pediatric patients for acute myelogenous leukemia but worse for acute lymphoblastic leukemia. Outcomes for both leukemias are better in AYA patients compared with older adults. Comparing the time periods 2000 to 2009 and 2010 to 2019 revealed significant improvement in overall survival across the age spectrum, but the greatest improvement in the AYA age group.

Original language	English (US)
Pages (from-to)	409.e1-409.e10
Journal	Transplantation and Cellular Therapy
Volume	28
Issue number	7
DOIs	https://doi.org/10.1016/j.jtct.2022.04.012
State	Published - Jul 2022

Bibliographical note

Funding Information:
Financial disclosure: The CIBMTR is supported primarily by Public Health Service Grant U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant HHSH250201700006C from the Health Resources and Services Administration (HRSA); and Awards N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research. Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and the following commercial entities: AbbVie, Accenture, Actinium Pharmaceuticals, Adaptive Biotechnologies, Adienne SA, Allovir, Amgen, Astellas Pharma US, bluebird bio, Bristol Myers Squibb, CareDx, CSL Behring, CytoSen Therapeutics, Daiichi Sankyo, Eurofins Viracor (DBA Eurofins Transplant Diagnostics), Fate Therapeutics, Gamida Cell, Gilead, GlaxoSmithKline, HistoGenetics, Incyte, Iovance, Janssen Research & Development, Janssen/Johnson & Johnson, Jasper Therapeutics, Jazz Pharmaceuticals, Kadmon; Karius; Karyopharm Therapeutics; Kiadis Pharma; Kite Pharma, Kyowa Kirin International, Legend Biotech, Magenta Therapeutics, Medac, Medexus, Merck & Co, Millennium, Miltenyi Biotec, MorphoSys; Novartis Pharmaceuticals, Omeros, OncoImmune, Oncopeptides, OptumHealth, Orca Biosystems, Ossium Health, Pfizer, Pharmacyclics, Priothera, Sanofi Genzyme, Seagen, Stemcyte, Takeda Pharmaceuticals, Talaris Therapeutics, Terumo Blood and Cell Technologies, TG Therapeutics, Tscan, Vertex, Vor Biopharma, and Xenikos BV.

Funding Information:
Financial disclosure: The CIBMTR is supported primarily by Public Health Service Grant U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant HHSH250201700006C from the Health Resources and Services Administration (HRSA); and Awards N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research. Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and the following commercial entities: AbbVie, Accenture, Actinium Pharmaceuticals, Adaptive Biotechnologies, Adienne SA, Allovir, Amgen, Astellas Pharma US, bluebird bio, Bristol Myers Squibb, CareDx, CSL Behring, CytoSen Therapeutics, Daiichi Sankyo, Eurofins Viracor (DBA Eurofins Transplant Diagnostics), Fate Therapeutics, Gamida Cell, Gilead, GlaxoSmithKline, HistoGenetics, Incyte, Iovance, Janssen Research & Development, Janssen/Johnson & Johnson, Jasper Therapeutics, Jazz Pharmaceuticals, Kadmon; Karius; Karyopharm Therapeutics; Kiadis Pharma; Kite Pharma, Kyowa Kirin International, Legend Biotech, Magenta Therapeutics, Medac, Medexus, Merck & Co, Millennium, Miltenyi Biotec, MorphoSys; Novartis Pharmaceuticals, Omeros, OncoImmune, Oncopeptides, OptumHealth, Orca Biosystems, Ossium Health, Pfizer, Pharmacyclics, Priothera, Sanofi Genzyme, Seagen, Stemcyte, Takeda Pharmaceuticals, Talaris Therapeutics, Terumo Blood and Cell Technologies, TG Therapeutics, Tscan, Vertex, Vor Biopharma, and Xenikos BV. Conflict of interest statement: There are no conflicts of interest to report. Data use statement: The CIBMTR supports accessibility of research in accordance with the NIH Data Sharing Policy and the NCI Cancer Moonshot Public Access and Data Sharing Policy. The CIBMTR releases only deidentified datasets that comply with all relevant global regulations regarding privacy and confidentiality. Financial disclosure: See Acknowledgments on page 409.e9.

Publisher Copyright:
© 2022

Keywords

Activity
Adolescent and young adult
Hematopoietic cell transplantation
Summary slides

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.jtct.2022.04.012

Find It

Find It at U of M Libraries

Cite this

Phelan, R., Chen, M., Bupp, C., Bolon, Y. T., Broglie, L., Brunner-Grady, J., Burns, L. J., Chhabra, S., Christianson, D., Cusatis, R., Devine, S. M., D'Souza, A., Eapen, M., Hamadani, M., Hengen, M., Lee, S. J., Moskop, A., Page, K. M., Pasquini, M., ... Arora, M. (2022). Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplantation and Cellular Therapy, 28(7), 409.e1-409.e10. https://doi.org/10.1016/j.jtct.2022.04.012

Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. / Phelan, Rachel; Chen, Min; Bupp, Caitrin et al.
In: Transplantation and Cellular Therapy, Vol. 28, No. 7, 07.2022, p. 409.e1-409.e10.

Research output: Contribution to journal › Article › peer-review

Phelan, R, Chen, M, Bupp, C, Bolon, YT, Broglie, L, Brunner-Grady, J, Burns, LJ, Chhabra, S, Christianson, D, Cusatis, R, Devine, SM, D'Souza, A, Eapen, M, Hamadani, M, Hengen, M, Lee, SJ, Moskop, A, Page, KM, Pasquini, M, Pérez, WS, Riches, M, Rizzo, D, Saber, W, Spellman, SR, Stefanski, HE, Steinert, P, Weisdorf, D, Horowitz, M, Auletta, JJ, Shaw, BE & Arora, M 2022, 'Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes', Transplantation and Cellular Therapy, vol. 28, no. 7, pp. 409.e1-409.e10. https://doi.org/10.1016/j.jtct.2022.04.012

@article{56c08926216543ae972bf2626c9985f5,

title = "Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes",

abstract = "Hematopoietic cell transplantation (HCT) has been successfully used to treat many malignant and nonmalignant conditions. As supportive care, donor selection, and treatment modalities evolve, documenting HCT trends and outcomes is critical. This report from the Center for International Blood and Marrow Transplant Research (CIBMTR) provides an update on current transplantation activity and survival rates in the United States. Additional data on the use and outcomes of HCT in the adolescent and young adult (AYA) population are included. AYA patients more frequently receive peripheral blood stem cell grafts than pediatric patients, which may reflect differences in practice in pediatric versus adult treatment centers. The proportions of donor types also differ those in adult and pediatric populations. Outcomes for patients in the AYA age range are similar to those of pediatric patients for acute myelogenous leukemia but worse for acute lymphoblastic leukemia. Outcomes for both leukemias are better in AYA patients compared with older adults. Comparing the time periods 2000 to 2009 and 2010 to 2019 revealed significant improvement in overall survival across the age spectrum, but the greatest improvement in the AYA age group.",

keywords = "Activity, Adolescent and young adult, Hematopoietic cell transplantation, Summary slides",

author = "Rachel Phelan and Min Chen and Caitrin Bupp and Bolon, {Yung Tsi} and Larisa Broglie and Janet Brunner-Grady and Burns, {Linda J.} and Saurabh Chhabra and Debra Christianson and Rachel Cusatis and Devine, {Steven M.} and Anita D'Souza and Mary Eapen and Mehdi Hamadani and Mary Hengen and Lee, {Stephanie J.} and Amy Moskop and Page, {Kristin M.} and Marcelo Pasquini and P{\'e}rez, {Waleska S.} and Marcie Riches and Doug Rizzo and Wael Saber and Spellman, {Stephen R.} and Stefanski, {Heather E.} and Patricia Steinert and Daniel Weisdorf and Mary Horowitz and Auletta, {Jeffery J.} and Shaw, {Bronwen E.} and Mukta Arora",

note = "Funding Information: Financial disclosure: The CIBMTR is supported primarily by Public Health Service Grant U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant HHSH250201700006C from the Health Resources and Services Administration (HRSA); and Awards N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research. Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and the following commercial entities: AbbVie, Accenture, Actinium Pharmaceuticals, Adaptive Biotechnologies, Adienne SA, Allovir, Amgen, Astellas Pharma US, bluebird bio, Bristol Myers Squibb, CareDx, CSL Behring, CytoSen Therapeutics, Daiichi Sankyo, Eurofins Viracor (DBA Eurofins Transplant Diagnostics), Fate Therapeutics, Gamida Cell, Gilead, GlaxoSmithKline, HistoGenetics, Incyte, Iovance, Janssen Research & Development, Janssen/Johnson & Johnson, Jasper Therapeutics, Jazz Pharmaceuticals, Kadmon; Karius; Karyopharm Therapeutics; Kiadis Pharma; Kite Pharma, Kyowa Kirin International, Legend Biotech, Magenta Therapeutics, Medac, Medexus, Merck & Co, Millennium, Miltenyi Biotec, MorphoSys; Novartis Pharmaceuticals, Omeros, OncoImmune, Oncopeptides, OptumHealth, Orca Biosystems, Ossium Health, Pfizer, Pharmacyclics, Priothera, Sanofi Genzyme, Seagen, Stemcyte, Takeda Pharmaceuticals, Talaris Therapeutics, Terumo Blood and Cell Technologies, TG Therapeutics, Tscan, Vertex, Vor Biopharma, and Xenikos BV. Funding Information: Financial disclosure: The CIBMTR is supported primarily by Public Health Service Grant U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant HHSH250201700006C from the Health Resources and Services Administration (HRSA); and Awards N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research. Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and the following commercial entities: AbbVie, Accenture, Actinium Pharmaceuticals, Adaptive Biotechnologies, Adienne SA, Allovir, Amgen, Astellas Pharma US, bluebird bio, Bristol Myers Squibb, CareDx, CSL Behring, CytoSen Therapeutics, Daiichi Sankyo, Eurofins Viracor (DBA Eurofins Transplant Diagnostics), Fate Therapeutics, Gamida Cell, Gilead, GlaxoSmithKline, HistoGenetics, Incyte, Iovance, Janssen Research & Development, Janssen/Johnson & Johnson, Jasper Therapeutics, Jazz Pharmaceuticals, Kadmon; Karius; Karyopharm Therapeutics; Kiadis Pharma; Kite Pharma, Kyowa Kirin International, Legend Biotech, Magenta Therapeutics, Medac, Medexus, Merck & Co, Millennium, Miltenyi Biotec, MorphoSys; Novartis Pharmaceuticals, Omeros, OncoImmune, Oncopeptides, OptumHealth, Orca Biosystems, Ossium Health, Pfizer, Pharmacyclics, Priothera, Sanofi Genzyme, Seagen, Stemcyte, Takeda Pharmaceuticals, Talaris Therapeutics, Terumo Blood and Cell Technologies, TG Therapeutics, Tscan, Vertex, Vor Biopharma, and Xenikos BV. Conflict of interest statement: There are no conflicts of interest to report. Data use statement: The CIBMTR supports accessibility of research in accordance with the NIH Data Sharing Policy and the NCI Cancer Moonshot Public Access and Data Sharing Policy. The CIBMTR releases only deidentified datasets that comply with all relevant global regulations regarding privacy and confidentiality. Financial disclosure: See Acknowledgments on page 409.e9. Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jul,

doi = "10.1016/j.jtct.2022.04.012",

language = "English (US)",

volume = "28",

pages = "409.e1--409.e10",

journal = "Transplantation and Cellular Therapy",

issn = "2666-6367",

publisher = "Elsevier BV",

number = "7",

}

TY - JOUR

T1 - Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes

AU - Phelan, Rachel

AU - Chen, Min

AU - Bupp, Caitrin

AU - Bolon, Yung Tsi

AU - Broglie, Larisa

AU - Brunner-Grady, Janet

AU - Burns, Linda J.

AU - Chhabra, Saurabh

AU - Christianson, Debra

AU - Cusatis, Rachel

AU - Devine, Steven M.

AU - D'Souza, Anita

AU - Eapen, Mary

AU - Hamadani, Mehdi

AU - Hengen, Mary

AU - Lee, Stephanie J.

AU - Moskop, Amy

AU - Page, Kristin M.

AU - Pasquini, Marcelo

AU - Pérez, Waleska S.

AU - Riches, Marcie

AU - Rizzo, Doug

AU - Saber, Wael

AU - Spellman, Stephen R.

AU - Stefanski, Heather E.

AU - Steinert, Patricia

AU - Weisdorf, Daniel

AU - Horowitz, Mary

AU - Auletta, Jeffery J.

AU - Shaw, Bronwen E.

AU - Arora, Mukta

N1 - Funding Information: Financial disclosure: The CIBMTR is supported primarily by Public Health Service Grant U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant HHSH250201700006C from the Health Resources and Services Administration (HRSA); and Awards N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research. Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and the following commercial entities: AbbVie, Accenture, Actinium Pharmaceuticals, Adaptive Biotechnologies, Adienne SA, Allovir, Amgen, Astellas Pharma US, bluebird bio, Bristol Myers Squibb, CareDx, CSL Behring, CytoSen Therapeutics, Daiichi Sankyo, Eurofins Viracor (DBA Eurofins Transplant Diagnostics), Fate Therapeutics, Gamida Cell, Gilead, GlaxoSmithKline, HistoGenetics, Incyte, Iovance, Janssen Research & Development, Janssen/Johnson & Johnson, Jasper Therapeutics, Jazz Pharmaceuticals, Kadmon; Karius; Karyopharm Therapeutics; Kiadis Pharma; Kite Pharma, Kyowa Kirin International, Legend Biotech, Magenta Therapeutics, Medac, Medexus, Merck & Co, Millennium, Miltenyi Biotec, MorphoSys; Novartis Pharmaceuticals, Omeros, OncoImmune, Oncopeptides, OptumHealth, Orca Biosystems, Ossium Health, Pfizer, Pharmacyclics, Priothera, Sanofi Genzyme, Seagen, Stemcyte, Takeda Pharmaceuticals, Talaris Therapeutics, Terumo Blood and Cell Technologies, TG Therapeutics, Tscan, Vertex, Vor Biopharma, and Xenikos BV. Funding Information: Financial disclosure: The CIBMTR is supported primarily by Public Health Service Grant U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant HHSH250201700006C from the Health Resources and Services Administration (HRSA); and Awards N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research. Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and the following commercial entities: AbbVie, Accenture, Actinium Pharmaceuticals, Adaptive Biotechnologies, Adienne SA, Allovir, Amgen, Astellas Pharma US, bluebird bio, Bristol Myers Squibb, CareDx, CSL Behring, CytoSen Therapeutics, Daiichi Sankyo, Eurofins Viracor (DBA Eurofins Transplant Diagnostics), Fate Therapeutics, Gamida Cell, Gilead, GlaxoSmithKline, HistoGenetics, Incyte, Iovance, Janssen Research & Development, Janssen/Johnson & Johnson, Jasper Therapeutics, Jazz Pharmaceuticals, Kadmon; Karius; Karyopharm Therapeutics; Kiadis Pharma; Kite Pharma, Kyowa Kirin International, Legend Biotech, Magenta Therapeutics, Medac, Medexus, Merck & Co, Millennium, Miltenyi Biotec, MorphoSys; Novartis Pharmaceuticals, Omeros, OncoImmune, Oncopeptides, OptumHealth, Orca Biosystems, Ossium Health, Pfizer, Pharmacyclics, Priothera, Sanofi Genzyme, Seagen, Stemcyte, Takeda Pharmaceuticals, Talaris Therapeutics, Terumo Blood and Cell Technologies, TG Therapeutics, Tscan, Vertex, Vor Biopharma, and Xenikos BV. Conflict of interest statement: There are no conflicts of interest to report. Data use statement: The CIBMTR supports accessibility of research in accordance with the NIH Data Sharing Policy and the NCI Cancer Moonshot Public Access and Data Sharing Policy. The CIBMTR releases only deidentified datasets that comply with all relevant global regulations regarding privacy and confidentiality. Financial disclosure: See Acknowledgments on page 409.e9. Publisher Copyright: © 2022

PY - 2022/7

Y1 - 2022/7

N2 - Hematopoietic cell transplantation (HCT) has been successfully used to treat many malignant and nonmalignant conditions. As supportive care, donor selection, and treatment modalities evolve, documenting HCT trends and outcomes is critical. This report from the Center for International Blood and Marrow Transplant Research (CIBMTR) provides an update on current transplantation activity and survival rates in the United States. Additional data on the use and outcomes of HCT in the adolescent and young adult (AYA) population are included. AYA patients more frequently receive peripheral blood stem cell grafts than pediatric patients, which may reflect differences in practice in pediatric versus adult treatment centers. The proportions of donor types also differ those in adult and pediatric populations. Outcomes for patients in the AYA age range are similar to those of pediatric patients for acute myelogenous leukemia but worse for acute lymphoblastic leukemia. Outcomes for both leukemias are better in AYA patients compared with older adults. Comparing the time periods 2000 to 2009 and 2010 to 2019 revealed significant improvement in overall survival across the age spectrum, but the greatest improvement in the AYA age group.

AB - Hematopoietic cell transplantation (HCT) has been successfully used to treat many malignant and nonmalignant conditions. As supportive care, donor selection, and treatment modalities evolve, documenting HCT trends and outcomes is critical. This report from the Center for International Blood and Marrow Transplant Research (CIBMTR) provides an update on current transplantation activity and survival rates in the United States. Additional data on the use and outcomes of HCT in the adolescent and young adult (AYA) population are included. AYA patients more frequently receive peripheral blood stem cell grafts than pediatric patients, which may reflect differences in practice in pediatric versus adult treatment centers. The proportions of donor types also differ those in adult and pediatric populations. Outcomes for patients in the AYA age range are similar to those of pediatric patients for acute myelogenous leukemia but worse for acute lymphoblastic leukemia. Outcomes for both leukemias are better in AYA patients compared with older adults. Comparing the time periods 2000 to 2009 and 2010 to 2019 revealed significant improvement in overall survival across the age spectrum, but the greatest improvement in the AYA age group.

KW - Activity

KW - Adolescent and young adult

KW - Hematopoietic cell transplantation

KW - Summary slides

UR - http://www.scopus.com/inward/record.url?scp=85130441260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130441260&partnerID=8YFLogxK

U2 - 10.1016/j.jtct.2022.04.012

DO - 10.1016/j.jtct.2022.04.012

M3 - Article

C2 - 35447374

AN - SCOPUS:85130441260

SN - 2666-6367

VL - 28

SP - 409.e1-409.e10

JO - Transplantation and Cellular Therapy

JF - Transplantation and Cellular Therapy

IS - 7

ER -

Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this